Literature DB >> 25720519

Administration of umbilical cord blood cells transiently decreased hypoxic-ischemic brain injury in neonatal rats.

Tetsuo Hattori1, Yoshiaki Sato, Taiki Kondo, Yuko Ichinohashi, Yuichiro Sugiyama, Michiro Yamamoto, Tomomi Kotani, Hitoshi Hirata, Akihiro Hirakawa, Satoshi Suzuki, Masahiro Tsuji, Tomoaki Ikeda, Keiko Nakanishi, Seiji Kojima, Klas Blomgren, Masahiro Hayakawa.   

Abstract

This study aimed to investigate whether the administration of mononuclear cells derived from human umbilical cord blood cells (UCBCs) could ameliorate hypoxic-ischemic brain injury in a neonatal rat model. The left carotid arteries of 7-day-old rats were ligated, and the rats were then exposed to 8% oxygen for 60 min. Mononuclear cells derived from UCBCs using the Ficoll-Hypaque technique were injected intraperitoneally 6 h after the insult (1.0 × 10(7) cells). Twenty-four hours after the insult, the number of cells positive for the oxidative stress markers 4-hydroxy-2-nonenal and nitrotyrosine, in the dentate gyrus of the hippocampus in the UCBC-treated group, decreased by 36 and 42%, respectively, compared with those in the control group. In addition, the number of cells positive for the apoptosis markers active caspase-3 and apoptosis-inducing factor decreased by 53 and 58%, respectively. The number of activated microglia (ED1-positive cells) was 51% lower in the UCBC group compared with the control group. In a gait analysis performed 2 weeks after the insult, there were no significant differences among the sham-operated, control and UCBC groups. An active avoidance test using a shuttle box the following week also revealed no significant differences among the groups. Neither the volumes of the hippocampi, corpus callosum and cortices nor the numbers of neurons in the hippocampus were different between the UCBC and control groups. In summary, a single intraperitoneal injection of UCBC-derived mononuclear cells 6 h after an ischemic insult was associated with a transient reduction in numbers of apoptosis and oxidative stress marker-positive cells, but it did not induce long-term morphological or functional protection. Repeated administration or a combination treatment may be required to achieve sustained protection.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 25720519     DOI: 10.1159/000368396

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  20 in total

Review 1.  Future perspectives of cell therapy for neonatal hypoxic-ischemic encephalopathy.

Authors:  Makoto Nabetani; Haruo Shintaku; Takashi Hamazaki
Journal:  Pediatr Res       Date:  2017-11-08       Impact factor: 3.756

Review 2.  Microglia and Stem-Cell Mediated Neuroprotection after Neonatal Hypoxia-Ischemia.

Authors:  Catherine Brégère; Bernd Schwendele; Boris Radanovic; Raphael Guzman
Journal:  Stem Cell Rev Rep       Date:  2021-08-11       Impact factor: 5.739

3.  Intravenously delivered multilineage-differentiating stress enduring cells dampen excessive glutamate metabolism and microglial activation in experimental perinatal hypoxic ischemic encephalopathy.

Authors:  Toshihiko Suzuki; Yoshiaki Sato; Yoshihiro Kushida; Masahiro Tsuji; Shohei Wakao; Kazuto Ueda; Kenji Imai; Yukako Iitani; Shinobu Shimizu; Hideki Hida; Takashi Temma; Shigeyoshi Saito; Hidehiro Iida; Masaaki Mizuno; Yoshiyuki Takahashi; Mari Dezawa; Cesar V Borlongan; Masahiro Hayakawa
Journal:  J Cereb Blood Flow Metab       Date:  2020-11-22       Impact factor: 6.200

4.  Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial.

Authors:  Nao Matsuyama; Shinobu Shimizu; Kazuto Ueda; Toshihiko Suzuki; Sakiko Suzuki; Ryosuke Miura; Akemi Katayama; Masahiko Ando; Masaaki Mizuno; Akihiro Hirakawa; Masahiro Hayakawa; Yoshiaki Sato
Journal:  BMJ Open       Date:  2022-04-26       Impact factor: 3.006

5.  Brain caspase-3 and intestinal FABP responses in preterm and term rats submitted to birth asphyxia.

Authors:  R L Figueira; F L Gonçalves; A L Simões; C A Bernardino; L S Lopes; O Castro E Silva; L Sbragia
Journal:  Braz J Med Biol Res       Date:  2016-06-23       Impact factor: 2.590

6.  Dose-Dependent Effect of Intravenous Administration of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Neonatal Stroke Mice.

Authors:  Emi Tanaka; Yuko Ogawa; Takeo Mukai; Yoshiaki Sato; Takashi Hamazaki; Tokiko Nagamura-Inoue; Mariko Harada-Shiba; Haruo Shintaku; Masahiro Tsuji
Journal:  Front Neurol       Date:  2018-03-08       Impact factor: 4.003

7.  Umbilical cord blood therapy modulates neonatal hypoxic ischemic brain injury in both females and males.

Authors:  Tayla R Penny; Yen Pham; Amy E Sutherland; Joohyung Lee; Graham Jenkin; Michael C Fahey; Suzanne L Miller; Courtney A McDonald
Journal:  Sci Rep       Date:  2021-08-04       Impact factor: 4.379

8.  Protective mechanisms of microRNA-27a against oxygen-glucose deprivation-induced injuries in hippocampal neurons.

Authors:  Qun Cai; Ting Wang; Wen-Jie Yang; Xing Fen
Journal:  Neural Regen Res       Date:  2016-08       Impact factor: 5.135

9.  Rat umbilical cord blood cells attenuate hypoxic-ischemic brain injury in neonatal rats.

Authors:  Keiko Nakanishi; Yoshiaki Sato; Yuka Mizutani; Miharu Ito; Akihiro Hirakawa; Yujiro Higashi
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

10.  Autologous transplantation of umbilical cord blood-derived cells in extreme preterm infants: protocol for a safety and feasibility study.

Authors:  Atul Malhotra; Iona Novak; Suzanne Lee Miller; Graham Jenkin
Journal:  BMJ Open       Date:  2020-05-11       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.